Jeena Sikho Lifecare Ltd Forensic Report - SOIC x StockScans Report

as of Sep 2026

Jeena Sikho Lifecare’s FY2025-26 record carries a clean audit opinion, but that opinion sits on top of a year of firsts: a first-time consolidated group built around a UAE free-zone subsidiary, a first-time Ind AS transition, and a mid-tenure auditor resignation. The goodwill from the Oregano Life acquisition is supported by assumptions the auditors stress-tested, yet the acquired unit contributed only ₹8 crore of revenue. The more concrete issues are the company’s own contradictory related-party disclosures and a qualified CARO finding on ₹1,897 lacs of fixed-asset records.

Key findings

  1. A ₹58 crore goodwill asset rests on a ₹1,788 crore value-in-use assumption Major - Jeena Sikho acquired five Ayurvedic Therapy Centre branches from Oregano Life Private Limited on 3 Oct 2024 for ₹69.16 crore, and booked goodwill of ₹58.12 crore against that unit as at 31 Mar 2026. The recoverable amount was set at ₹1,788.02 crore using a 4% terminal growth rate and 13.55% discount rate, with no impairment recognised. The acquired business contributed just ₹8.03 crore of revenue, and the company switched from 16-year amortisation under previous GAAP to an indefinite life on Ind AS transition.
  2. The company’s own disclosures contradict each other on related-party deals Major - The FY2025-26 Board’s Report states in AOC-2 that no material related-party transactions occurred, while the forensic sweep shows ₹4.91 crore of sales and royalty to Shuddhi Lifecare Private Limited in the same year. The AGM notice seeks approval for up to ₹100 crore in loans under Section 185 and ₹700 crore in investments under Section 186. The FY2024-25 auditor had already flagged a 2.12 crore interest-free loan to erstwhile subsidiary Shuddhi Charcoal Private Limited as prejudicial to the company’s interest.
  3. First-time consolidation adds a UAE subsidiary that committed ₹19.4 crore to an unfinished deal Major - Jeena Sikho had no subsidiaries as at 31 Mar 2024, but by 31 Mar 2026 it had two, including wholly-owned Jeena Sikho International LLC, incorporated under Sharjah Media City Free Zone on 11 Sep 2025. That subsidiary signed a Share Purchase Agreement on 7 Jan 2026 to buy 51% of Back to Roots Ayurveda by Dr. Shyam LLC for AED 75.30 lakhs (₹19.40 crore), of which AED 36.40 lakhs (₹9.38 crore) was disbursed by 31 Mar 2026. The share transfer remained pending regulatory formalities, and the amount sits as an advance for investment.
  4. Clean audit opinions, but a qualified CARO finding on fixed-asset records Major - Walker Chandiok & Co LLP issued unmodified opinions on the FY2026 standalone and consolidated statements. However, CARO clause 3(i)(a)(A) states proper records were NOT maintained for certain Furniture, Office equipment, Computers and Electrical equipment, covering a Gross Block of ₹1,897 lacs. The FY2025 CARO had flagged a 2.12 crore interest-free loan as prejudicial, and the FY2026 report carries a Section 143(3) exception on the audit-trail feature.
  5. Statutory auditor resigned mid-tenure in August 2025 Major - KRA & Co., appointed in November 2021 for a five-year term, resigned effective 14 Aug 2025 after completing the June 2025 limited review. Walker Chandiok & Co LLP was appointed to fill the casual vacancy the same day, and members approved a five-year term at the 29 Sep 2025 AGM. The company states no issues, objections or concerns were raised by the outgoing auditor.
  6. Revenue quality shifts as government-panel sales are cut by two-thirds Major - Government panel revenue was deliberately reduced from ₹117.8 crore to ₹36.0 crore, from 25% to 4% of revenue, to lower receivables risk. As at 31.03.2025, trade receivables showed ₹86.62 lakhs outstanding for more than 3 years and 7.85 crore in the 2-3 year bucket, with 2.05 crore of doubtful debts fully provided for. Related-party receivables rose from ₹6.04 lakhs to ₹67.55 lakhs during FY2025-26, and revenue recognition was flagged as a key audit matter in the consolidated audit.
  7. A promoter family holds all three executive seats; public institutions voted against the promoter’s daughter Major - The Board as at 31 Mar 2026 comprised Mr. Manish Grover, his spouse Mrs. Bhavna Grover, and their daughter Ms. Shreya Grover as the only Executive Directors. At the 29 Sep 2025 AGM, Public-Institutions voted 100% against the reappointment of Ms. Shreya Grover and against the ESOP 2025 scheme, though both resolutions passed with over 99% overall support. The Company Secretary position changed three times in roughly 12 months, with resignations effective 1 Aug 2025 and 14 Jul 2026.
  8. FY2025-26 is a wholesale shift to Ind AS with restatements and first-time charges Major - The opening balance sheet at 1 Apr 2024 was restated, with goodwill reassessed to an indefinite life and recomputed under purchase price allocation. The New Labour Codes, effective 21 Nov 2025, produced a 1.25 crore charge in the FY2025-26 P&L, and compensated absences of ₹33.79 lakh were recognised for the first time. Gratuity actuarial gains and losses moved to OCI, ESOP expense was recorded at fair value, and deferred tax was computed under the balance-sheet approach.

What to watch

Bottom line: This is an audited record with a clean opinion, but the opinion is new, the auditor is new, and the accounting framework is new. The risk character is one of rapid structural change, a first-time group, a first-time Ind AS transition, and a promoter family that controls both the board and the related-party counter-parties. Watch the unfinished UAE acquisition, the shareholder votes on the new loan authorities, and whether the goodwill assumption survives next year’s impairment test.